These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 32245480)

  • 1. The effect of comprehensive rehabilitation program plus chemotherapy on quality of life in patients with postoperative non-small-cell lung cancer: study protocol of a multicenter randomized clinical trial.
    Yao J; Jiao L; Yao Y; Lu Y; Shi J; Li J; Chen P; Xu L; Gong Y
    Trials; 2020 Apr; 21(1):309. PubMed ID: 32245480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-center randomized double-blind controlled clinical study of chemotherapy combined with or without traditional Chinese medicine on quality of life of postoperative non-small cell lung cancer patients.
    Xu L; Li H; Xu Z; Wang Z; Liu L; Tian J; Sun J; Zhou L; Yao Y; Jiao L; Su W; Guo H; Chen P; Liu J
    BMC Complement Altern Med; 2012 Aug; 12():112. PubMed ID: 22853619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.
    Yang XB; Wu WY; Long SQ; Deng H; Pan ZQ; He WF; Zhou YS; Liao GY; Li QP; Xiao SJ; Cai JZ
    Trials; 2015 Apr; 16():146. PubMed ID: 25873045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of first-line chemotherapy with Kanglaite injections versus first-line chemotherapy alone for advanced non-small-cell lung cancer: study protocol for an investigator-initiated, multicenter, open-label, randomized controlled trial.
    Gao R; Zhang Y; Hou W; Li J; Zhu G; Zhang X; Xu B; Wu Z; Wang H
    Trials; 2021 Mar; 22(1):214. PubMed ID: 33731199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Traditional Chinese Medicine Treatment as Adjuvant Therapy in Completely Resected Stage IB-IIIA Non-Small-Cell Lung Cancer: Study Protocol for a Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.
    Jiang Y; Liu LS; Shen LP; Liu JX; Jiang GN; Gu AQ; Li HC; Li Q; Li HG; Huang PX
    Clin Lung Cancer; 2019 Sep; 20(5):e541-e547. PubMed ID: 31230892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chinese Herbal Medicine for Improving Quality of Life Among Nonsmall Cell Lung Cancer Patients: Overview of Systematic Reviews and Network Meta-Analysis.
    Wu X; Chung VCH; Lu P; Poon SK; Hui EP; Lau AYL; Balneaves LG; Wong SYS; Wu JCY
    Medicine (Baltimore); 2016 Jan; 95(1):e2410. PubMed ID: 26735544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-Reported Outcomes of Postoperative NSCLC Patients with or without Staged Chinese Herb Medicine Therapy during Adjuvant Chemotherapy (NALLC 2): A Randomized, Double-Blind, Placebo-Controlled Trial.
    Zhang YL; Jiao LJ; Gong YB; Xu JF; Ni J; Shen XY; Zhang J; Zhou D; Qian CX; Wang Q; Yao JL; Yang WX; Su LZ; Wang LY; Li JQ; Yao YQ; Zhang YH; Wang YC; Chen ZW; Xu L
    Chin J Integr Med; 2024 Nov; 30(11):963-973. PubMed ID: 39266862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of Jianpishengsui for chemotherapy-related fatigue in patients with non-small cell lung cancer: study protocol for a randomized placebo-controlled clinical trial.
    Xiao Z; Hu L; Lin J; Lu L; Huang X; Zhu X; Teo C; Lin L
    Trials; 2020 Jan; 21(1):94. PubMed ID: 31948475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive TCM treatments combined with chemotherapy for advanced non-small cell lung cancer: A randomized, controlled trial.
    Xiao Z; Chen Z; Han R; Lu L; Li Z; Lin J; Hu L; Huang X; Lin L
    Medicine (Baltimore); 2021 May; 100(18):e25690. PubMed ID: 33950949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.
    Yue D; Xu S; Wang Q; Li X; Shen Y; Zhao H; Chen C; Mao W; Liu W; Liu J; Zhang L; Ma H; Li Q; Yang Y; Liu Y; Chen H; Wang C
    Lancet Respir Med; 2018 Nov; 6(11):863-873. PubMed ID: 30150014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of traditional Chinese medicine combined with chemotherapy for extensive-stage small-cell lung cancer patients on improving oncologic survival: study protocol of a multicenter, randomized, single-blind, placebo-controlled trial.
    Chen Y; Yu M; Liu Z; Zhang Y; Li Q; Yang G
    Trials; 2021 Jul; 22(1):437. PubMed ID: 34238342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chinese herbal medicine as maintenance therapy for improving the quality of life for advanced non-small cell lung cancer patients.
    Han Y; Wang H; Xu W; Cao B; Han L; Jia L; Xu Y; Zhang Q; Wang X; Zhang G; Yu M; Yang G
    Complement Ther Med; 2016 Feb; 24():81-9. PubMed ID: 26860807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).
    Zhang Z; Luo F; Zhang Y; Ma Y; Hong S; Yang Y; Fang W; Huang Y; Zhang L; Zhao H
    Cancer Commun (Lond); 2019 Nov; 39(1):69. PubMed ID: 31699150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
    Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
    Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter randomized controlled trial to assess the efficacy of cancer green therapy in treatment of stage IIIb/IV non-small cell lung cancer.
    Sun M; Zhou T; Fang X; Wang D; Pang H; Chen Y; Hu K
    Medicine (Baltimore); 2020 Aug; 99(33):e21626. PubMed ID: 32872022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review and meta-analysis of Chinese herbal medicine as adjuvant treatment in advanced non-small cell lung cancer patients.
    Wang LC; Chang YY; Lee IC; Kuo HC; Tsai MY
    Complement Ther Med; 2020 Aug; 52():102472. PubMed ID: 32951722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of gefitinib plus Chinese herbal medicine (CHM) in patients with advanced non-small-cell lung cancer: a retrospective case-control study.
    Yang XB; Wu WY; Long SQ; Deng H; Pan ZQ
    Complement Ther Med; 2014 Dec; 22(6):1010-8. PubMed ID: 25453521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of Radical Resected NSCLC by Chinese Medicine Combined with Adjuvant Chemother- apy: a Clinical Study].
    Hou WX; Li HG; Chen ZW; Zhu LH; Zhao LH; Tian JH; Xu WJ; Zhou L; Yao YL
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2015 Jun; 35(6):648-53. PubMed ID: 26242112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Could Jinfukang alleviate the chemotherapy-related adverse effects in non-small cell lung cancer patients?: A protocol for a double-blind, randomized controlled trial.
    Zheng X; Wang W; Wang G; Liu S
    Medicine (Baltimore); 2021 Jul; 100(28):e25002. PubMed ID: 34260519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral Chinese herbal medicine (CHM) as an adjuvant treatment during chemotherapy for non-small cell lung cancer: A systematic review.
    Chen S; Flower A; Ritchie A; Liu J; Molassiotis A; Yu H; Lewith G
    Lung Cancer; 2010 May; 68(2):137-45. PubMed ID: 20015572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.